Neil Harris Cohen
Known title: DirectorCIK: 0001840006
Neil Harris Cohen's purchase track record
How the stock did after each of Neil Harris Cohen's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since December 6, 2021
Stock higher 6 months later
0%
3 months: 33%
Median 6-month return
-25.5%
3 months: -15.4%
Beat the S&P 500
0%
median -26.4% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/18/2022 | CMMB | $6K | +6.9% | -25.5% | +0.9% |
| 3/14/2022 | CMMB | $26K | -15.4% | -13.4% | -1.5% |
| 12/6/2021 | CMMB | $15K | -52.5% | -54.4% | -10.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CMMB | ▼ Sell | Open Market | 1,000 | $3K | 8/28/2026 | View on chart |
| CMMB | ▼ Sell | Open Market | 1,304 | $4K | 8/27/2026 | View on chart |
| CMMB | ▼ Sell | Open Market | 2,409 | $5K | 11/16/2022 | View on chart |
| CMMB | ▲ Buy | Open Market | 2,000 | $6K | 5/18/2022 | View on chart |
| CMMB | ▲ Buy | Open Market | 2,000 | $8K | 3/14/2022 | View on chart |
| CMMB | ▲ Buy | Open Market | 2,000 | $9K | 3/14/2022 | View on chart |
| CMMB | ▲ Buy | Open Market | 2,000 | $9K | 3/14/2022 | View on chart |
| CMMB | ▲ Buy | Open Market | 2,000 | $15K | 12/6/2021 | View on chart |
| CMMB | ▲ Buy | Open Market | 2,409 | $100K | 3/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Chemomab Amends Merger Agreement for U.S. Redomiciliation
Chemomab has amended its merger agreement to facilitate a U.S. redomiciliation and combination with Scipher. This corporate restructuring is a significant development for the company's structure. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding these changes.
Chemomab Amends Merger Agreement for U.S. Redomiciliation. Chemomab has amended its merger agreement to facilitate a U.S. redomiciliation and combination with Scipher. This corporate restructuring is a significant development for the company's structure. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding these changes.